Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis
Exertional symptoms including at least one of the following:
* New York Heart Association (NYHA) Class ≥ II dyspnea
* Canadian Cardiovascular Society (CCS) Class ≥ II angina
Screening (baseline) peak VO2 \< 80% of predicted for age, sex, and weight
Ability to perform an upright treadmill cardiopulmonary exercise test (CPET)
You may not be if
Known aortic valve stenosis (moderate or severe)
Known coronary artery disease
Left ventricular systolic dysfunction (ejection fraction \< 50%)
Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation) within six months prior to screening or such a procedure scheduled to occur during the study
Clareo Health | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
